Western blot analysis showed that alisertib downregulated c-Myc expression, a positive regulator of the chronic active BCR pathway [19], with significantly decreased expression of PI3K, BTK, BCL-2, and NF-kβ (Figure 2) in both MCL cell lines. This evidence concerns the gene BCL2 and mantle cell lymphoma.